BODK Secures Tens of Millions in Pre-A Funding to Accelerate Life Science Robotics R&D

VCBeat has learned that Guangdong Bogong Sanluwu Robot Technology Co., Ltd. (hereinafter referred to as “Bogong Tech”) recently announced the completion of its Pre-A financing round, raising tens of millions of yuan. The round was led by Lime Capital, with CHINA PEAKEDNESS serving as the exclusive financial advisor. The funds raised will be used to accelerate the R&D and marketization of life science robotics products, providing support for the development of life science research and the smart healthcare industry.

Bogong Technology, established in 2022, is a high-tech innovative enterprise dedicated to the research and development of life science robotics and the practical application of artificial intelligence in life science scenarios. It continuously provides comprehensive, fully digitalized solutions for smart healthcare in the life sciences sector.

By integrating customer-specific application scenarios, Bogong Technology has entered the field of stem cell cultivation. Its independently developed core products, including incubator robots, centrifuge robots, and liquid nitrogen cryopreservation robots, have been successfully applied in stem cell cultivation settings, enabling factory-scale production of cell preparation processes. Bogong Technology will accelerate R&D in areas such as cell and gene therapy, antibody drugs, and biologics, contributing to the automation and domestication of life science instruments.

Currently, Bogong Technology operates a 2,000-square-meter intelligent laboratory and GMP-like production workshops. The company has filed nearly 100 patent applications and has independently designed and developed automated instruments and product lines that meet the needs of various smart healthcare application scenarios in the life sciences sector.

Bogong Technology owns the Robot 365 Life Science Robotics Technology Platform, with its core team members possessing over ten years of professional experience in AI robotics technology. The company has currently deployed industrial solutions for intelligent cell production, spanning from automation to digitalization, from high-throughput to high-quality, and from research services to clinical applications; it has established a one-stop service ecosystem featuring visualization of precision medicine processes, process automation, and intelligent environmental control.

In the future, Bogong Technology will leverage its highly automated AI technology platform to become a high-tech company empowering life science applications such as cell and gene therapy, medical diagnostics, and biopharmaceutical R&D, by integrating artificial intelligence technologies into various workflows across these life science scenarios.

Liu Zhaoqiang, Founder of Bogong Technologystated: “We extend our sincere gratitude to Lime Capital for its recognition and support of Bogong. The Company’s automation solutions represent a new paradigm for the application of artificial intelligence in life science scenarios. With the iterative advancement of robotics technology, the trend toward intelligent and automated processes in research and development (R&D) and production within the biotechnology sector is inevitable. Leveraging years of industry experience and deep customer insights, Guangdong Bogong Sanluwu Robot Technology Co., Ltd. focuses on the R&D and manufacturing of automation solutions for the life sciences. Through continuous effort and innovative iteration, we are committed to providing global customers with superior products and services. We are confident that Bogong will become a significant driving force in revolutionizing R&D and manufacturing processes in the life sciences field.”

Zhang Yunpeng, Founder of Lime CapitalIt stated: “Robotics and artificial intelligence hold broad application prospects in healthcare, energy, materials, and other fields. Their expansion across various sectors requires upstream production capabilities to process massive volumes of raw materials and data information, with the demand and trend toward automated and intelligent R&D and manufacturing gradually becoming evident. The team at Guangdong Bogong Sanluwu Robot Technology Co., Ltd. possesses highly integrated multidisciplinary expertise in life science experimentation and software/hardware development, backed by over a decade of industry experience. In recent years, the team has rapidly achieved the design and implementation of automated products, earning high recognition from numerous clients in niche industries. Lime Capital Co.LTD is highly optimistic about and confident in the team’s ability to execute R&D initiatives and drive commercialization. We will continue to support Bogong Technology in growing into a leading representative of digital life science service enterprises.”

Lan Chunquan, Vice President of CHINA PEAKEDNESSCHINA PEAKEDNESS stated: “We are honored to have served as the exclusive financial advisor for Bogong Technology’s current round of financing, assisting the company in successfully closing this round. Medical robotics is a field with high technical barriers. As a leading domestic developer of life science robots, Bogong Technology’s founding team brings extensive experience in the robotics industry and a proven track record in entrepreneurship. Within just over a year of its establishment, the company launched six highly modular robotic products, which have been deployed across multiple downstream life science enterprises, demonstrating exceptional commercialization capabilities. We look forward to seeing the company continue to grow and strengthen, providing even higher-quality robotic solutions to life science enterprises.”